Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Everest Medicines has dosed the first subject with EVM16, the company’s personalised mRNA cancer vaccine, in the EVM16CX01 ...

AstraZeneca has reported positive “high-level” outcomes from the Phase III MATTERHORN trial of Imfinzi (durvalumab) with FLOT chemotherapy.

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...

Overall survival data was not yet mature with less than a quarter of the required number of events having occurred. Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human ...

J&J and Protagonist Therapeutics are collectively developing icotrokinra, which is poised to be an immunology blockbuster. Image credit: Emily frost / Shutterstock. Johnson & Johnson (J&J) and ...

The trial is structured for enrolling nearly 350 subjects. Credit: Joyseulay/Shutterstock. PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to ...

The Phase II and Phase III trials show the therapy is effective at dropping blood pressure. Image credit: Good dreams – Studio / Shutterstock. Mineralys Therapeutics’s oral hypertension therapy, ...

The company’s stock, listed on the Copenhagen market, dropped by 9% on the news, from a DKr598 ($86.91) market open on 0 March to a DKr544 low. Credit: Shutterstock / JHVEPhoto. Novo Nordisk’s ...

The company announced that at week 16, more than 83% of patients dosed with Ebglyss no longer required the use of concomitant therapies such as topical corticosteroids. Credit: Shutterstock / Kmpzzz.

The AI assistant aims to aid drug supply managers in accessing trial information via an “intuitive” chat interface. Credit: Wright Studio / Shutterstock. Clinical trial technology company Suvoda has ...